Vaxcyte stock catapulted Monday after its experimental pneumococcal vaccine proved it's not inferior to marketed shots from ...

The labels were allegedly applied to vials containing cheaper medicines and used to make them appear to be genuine Pfizer products.

Pfizer faces some major LoE headwinds, but the stock is cheap and offers a large dividend, offering a solid total return potential. Click to read more on PFE.

Detailed results are competitive with Dupixent and Ebglyss, but the drug lacks differentiation amid an increasingly ...

(NYSE: PFE) today presented detailed results from an ongoing Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate-t ...

Acquisition adds specialist injection moulding expertise, an experienced team and a strong platform for further growth ...

SYCUME® Significantly Improved Proptosis (Response Rate 60.4% / LS Mean Change from Baseline -1.88 mm) with Favorable Safety Profile in Participants with Inactive Thyroid Eye ...

Summary • China SXT Pharmaceuticals SXTC-47.16% (SXTC) shares crater by 44.51% to $0.1906 • Intraday volume explodes with a ...

NVO and PFE offer different growth paths, with diversified portfolios, pipelines and near-term challenges shaping their ...

Health authorities often advise people to get their flu vaccine by the end of October – but as an epidemiologist focusing on ...

VIENNA — More than half of all patients with moderate-to-severe atopic dermatitis of the hands and feet treated with lebrikizumab (Ebglyss) monotherapy in a phase 3b trial achieved the primary ...